×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
Yahoo Finance
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET...
1 month ago
Roche jumps ship on AC Immune
European Biotechnology
Roche jumps ship on AC Immune ... Genentech, Roche's US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing...
3 months ago
AD/PD 2024: AC Immune looks to second part of Phase II Parkinson's vaccine trial
Clinical Trials Arena
AD/PD 2024: AC Immune looks to second part of Phase II Parkinson's vaccine trial. The company held a session on the second day of the...
1 month ago
Roche Ends Longstanding Collaboration with AC Immune, Hands Back Assets
BioSpace
After showing some unfavorable results for its data, AC Immune on Monday announced it will be getting back its Alzheimer's disease...
3 months ago
AC Immune (ACIU) to Release Earnings on Friday
MarketBeat
AC Immune (NASDAQ:ACIU) will be releasing earnings on Friday, April 26, Yahoo Finance reports.
3 days ago
Leerink Partners Serves as Joint Bookrunner for AC Immune SA's (Nasdaq: ACIU) $50 Million Follow-On Offering
Leerink Partners
More Deal Announcements · Leerink Partners Serves as Lead-Left Bookrunner for Edgewise Therapeutics' (Nasdaq: EWTX) $240 Million Follow-On...
4 months ago
Women in Stem with Andrea Pfeifer
Drug Target Review
This October edition of our Women in Stem series spotlights Andrea Pfeifer, Co-Founder of AC Immune.
4 months ago
Roche's Genentech returns Alzheimer's assets to AC Immune
Fierce Biotech
Roche's Genentech returns Alzheimer's assets to AC Immune, cutting 18-year tie to the biotech ... Genentech is walking away from an 18-year...
3 months ago
AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial
markets.businessinsider.com
AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial · Related Stocks · Johnson & Johnson NewsMORE...
4 months ago
AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Simply Wall St
The AC Immune SA ( NASDAQ:ACIU ) share price has fared very poorly over the last month, falling by a substantial 30...
3 weeks ago